Antihistamines increase breast cancer survival

Antihistamines increase breast cancer survival

Second generation antihistamines, in particular Desloratadine and Loratadine, have been shown by Swedish Researchers to significantly increase survival in breast cancer patients who are both ER+ and ER-.

Published in J. Clinical Oncology 33, 2015, researchers from Oncology Departments in Lund, Sweden, Hakan Lars Olsson, Rickard Einefors, Per Broberg, analysed over 54,000 women with breast cancer on record between 2000 and 2008.

They then looked at those who had co-incidentally taken antihistamines and found a significant difference in survival rate. Their conclusions were very clear: “Women treated with second generation antihistamines have a better overall and Breast Cancer specific survival compared with non users regardless of age, history of allergy, ER stage and tumour stage”.

Two antihistamine performed particularly well - Desloratadine and Loratadine.

Chris Woollams, former Oxford University Biochemist and founder of CANCERactive said, “I am not in the least surprised by this finding. We know that cancer cell membranes are inflamed and sticky. This is how they can pick up fat and hide, or stick to other cancer cells to form tumours, or stick to blood vessel walls and other organs. It is an essential part of cancer spread or metastases. We have seen this before with Cimetidine and how that greatly increased survival following colorectal cancer surgery, and with prostate cancer.

What is interesting in this research is that it was a real life study with quite a large sample.

We have always suggested a small aspirin which has a similar anti-inflammatory, anti-metastatic effect; and we’ve always suggested Cimetidine if people with cancer were about to have surgery. In this research, the antihistamines increased survival whatever the condition of the patient. We recommend all people with cancer look into using antihistamines as part of their Integrative Treatment Programme”.

Go to: Can antihistamines like Cimetidine increase cancer survival


2017 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Chris'

Join Chris' NewsletterSignup today for free and be the first to get notified on new updates.